



Express Mail No.: EV 335 858 000 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Kois et al. Confirmation No.: 6698  
Application No.: 10/004,642 Group Art Unit: 1624  
Filed: December 4, 2001 Examiner: Ford, J.  
For: ANILINOPYRIMIDINE Attorney Docket No.: 10624-049-999  
DERIVATIVES AS IKK  
INHIBITORS AND  
COMPOSITIONS AND  
METHODS RELATED THERETO

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 and 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **DG-DJ**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." A copy of references **DG-DJ** is enclosed.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review each of the references identified on the attached Form PTO-1449, and that the references be made of record in the file history of the above-identified application.

12/31/2003 ANDDAF1 00000005 161150 10004642

02 FC:1806 180.00 DA

Pursuant to 37 C.F.R. §1.97(c), this Second Supplemental Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. §1.97(b) but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and pursuant to 37 C.F.R. §1.97(c)(2) is accompanied by the fee set forth in §1.17(p) estimated to be \$180.00. Accordingly, please charge the required fee of \$180.00 to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this document is enclosed for accounting purposes.

Date December 18, 2003

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*  
By: *Michael J. Brunner, Reg. No. 47,459* 35,203  
Anthony M. Insogna (Reg. No.)  
**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT  
Several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
10624-049-999	10/004,642
APPLICANT	
Kois et al.	
FILING DATE	GROUP
December 4, 2001	1624

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	DG	WO 99/53927	October 29, 1999	PCT					
	DH	WO 02/085396	October 31, 2002	PCT					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DI	Spiegelman et al., "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> 268:6823-6826 (1993).
DJ	Hirosumi et al., "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> 420:333-336 (2002).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



DEC 18 2003

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
10624-049-999	10/004,642
APPLICANT	
Kois et al.	
FILING DATE	GROUP
December 4, 2001	1624

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	BE	WO 99/01439	1/14/99	PCT					

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

BF	Aspenstrom et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6:70-77
BG	Baeuerle and Baichwal, 1997, "NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules", <i>Advances in Immunology</i> 65:111-137
CG	Manning et al., 1997, "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6:555-567
CL	Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186:941-953

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.